Trastuzumab inhibited tumor onset in F1 HER2/Delta16 and Delta16 mice but not in full-length HER2 mice, strengthening the concept that d16HER2 expression strongly contributes to tumor addiction to HER2 signaling and consequently susceptibility to HER2 blockade [40]. Here, ERBB2 is linked to neoplasm.